↑ 薬物リストへ　← 戻る

Topiramate    (DrugBank: Topiramate)

5 diseases
告示番号疾患名（ページ内リンク）臨床試験数
6パーキンソン病4
140ドラベ症候群2
144レノックス・ガストー症候群3
156レット症候群1
193プラダー・ウィリ症候群2

6. パーキンソン病　［臨床試験数：2,123，薬物数：2,046（DrugBank：324），標的遺伝子数：183，標的パスウェイ数：198］
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01789047
(ClinicalTrials.gov)		March 20137/2/2013Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseTopiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's DiseaseIdiopathic Parkinson's Disease;Drug Induced DyskinesiaDrug: Topiramate;Drug: Placebo;Drug: AmantadineRush University Medical CenterMichael J. Fox Foundation for Parkinson's ResearchTerminated30 Years90 YearsAll42Phase 2United States
2NCT00794313
(ClinicalTrials.gov)		September 200919/11/2008Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's DiseaseQuantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's DiseaseParkinson's DiseaseDrug: Amantadine 300 mg;Drug: Topiramate;Drug: Sugar PillOregon Health and Science UniversityNULLTerminated21 YearsN/AAll3N/AUnited States
3EUCTR2007-002467-27-GB
(EUCTR)		24/01/200826/11/2007Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramateAntidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias - Antidyskinetic properties of topiramate Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
MedDRA version: 13.1;Level: PT;Classification code 10013916;Term: Dyskinesia;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 13.1;Classification code 10061536;Term: Parkinson's disease;Level: HLT;Classification code 10034005;Term: Parkinson's disease and parkinsonism;System Organ Class: 10029205 - Nervous system disorders		Product Name: Topiramate
INN or Proposed INN: TOPIRAMATE		Salford Royal NHS Foundation TrustNULLNot RecruitingFemale: yes
Male: yes		United Kingdom
4NCT00296959
(ClinicalTrials.gov)		September 200423/2/2006Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's DiseaseAnti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced DyskinesiasParkinson's DiseaseDrug: topiramate (drug)University Health Network, TorontoNULLTerminated30 Years75 YearsBoth20Phase 2Canada

140. ドラベ症候群　［臨床試験数：83，薬物数：54（DrugBank：13），標的遺伝子数：48，標的パスウェイ数：62］
Searched query = "Dorabe syndrome", "Dravet syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 83 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2007-002198-30-IT
(EUCTR)		03/07/200717/01/2012A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET`S SYNDROME (SMEI), AND AUXILIARY PHARMACOGENETIC STUDYA MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET`S SYNDROME (SMEI), AND AUXILIARY PHARMACOGENETIC STUDY Dravet Syndrome
MedDRA version: 14.1;Level: PT;Classification code 10054859;Term: Myoclonic epilepsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Trade Name: stiripentolo
INN or Proposed INN: Other antiepileptics
Trade Name: TOPAMAX
INN or Proposed INN: Topiramate
Trade Name: FRISIUM*30CPS 10MG
INN or Proposed INN: Clobazam		Inserm-ISP Pole Recherches cliniques et thérapeutiquesNULLNot RecruitingFemale: yes
Male: yes		90Italy
2EUCTR2007-003702-95-IT
(EUCTR)		03/07/200707/09/2007A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET'S SYNDROME (SMEI) NOT ADEQUATELY CONTROLLED WITH CLOBAZAM AND VALPROATE, AND AUXILIARY PHARMACOGENETIC STUDY - NDA MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET'S SYNDROME (SMEI) NOT ADEQUATELY CONTROLLED WITH CLOBAZAM AND VALPROATE, AND AUXILIARY PHARMACOGENETIC STUDY - ND Dravet Syndrome
Level: PTClassification code 10054859		Trade Name: stiripentolo
Trade Name: TOPAMAX
INN or Proposed INN: Topiramate
Trade Name: FRISIUM*30CPS 10MG
INN or Proposed INN: Clobazam		ISTITUTO C. MONDINONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		90Italy

144. レノックス・ガストー症候群　［臨床試験数：80，薬物数：63（DrugBank：11），標的遺伝子数：49，標的パスウェイ数：59］
Searched query = "Lennox-Gastaut syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 80 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00297349
(ClinicalTrials.gov)		November 200324/2/2006A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With SeizuresAn Open-label Observation Study of Topiramate Administration as Adjuvant Therapy for Focal Epilepsy, Lennox-Gastaut Syndrome Epileptic Seizures and Generalized Tonoclonic Seizures in Adults and Children Aged 2 Years and OlderSeizures;EpilepsyDrug: TopiramateJanssen Cilag Pharmaceutica S.A.C.I., GreeceNULLCompleted2 YearsN/ABoth153N/ANULL
2NCT00004776
(ClinicalTrials.gov)		November 199324/2/2000Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut SyndromeLennox-Gastaut SyndromeDrug: topiramateNational Center for Research Resources (NCRR)University of California, Los AngelesCompleted4 Years30 YearsBoth10Phase 3NULL
3NCT00236756
(ClinicalTrials.gov)		August 19937/10/2005A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut SyndromeA Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.Epilepsy;SeizuresDrug: topiramateJohnson & Johnson Pharmaceutical Research & Development, L.L.C.NULLCompleted12 Months30 YearsBoth100Phase 3NULL

156. レット症候群　［臨床試験数：36，薬物数：49（DrugBank：19），標的遺伝子数：77，標的パスウェイ数：112］
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 36 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00004807
(ClinicalTrials.gov)		January 199524/2/2000Study of the Pathogenesis of Rett SyndromeRett SyndromeDrug: dextromethorphan;Drug: topiramate;Drug: DonepezilEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Johns Hopkins UniversityCompletedN/A45 YearsBoth120N/ANULL

193. プラダー・ウィリ症候群　［臨床試験数：95，薬物数：104（DrugBank：27），標的遺伝子数：50，標的パスウェイ数：63］
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 95 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02810483
(ClinicalTrials.gov)		December 201217/5/2016Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 WeeksRandomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 WeeksPrader-Willi SyndromeDrug: Topiramate;Drug: Placebo ComparatorAssistance Publique - Hôpitaux de ParisNULLTerminated12 Years45 YearsAll69Phase 3France
2NCT00065923
(ClinicalTrials.gov)		July 20021/8/2003Treatment of Self-Injurious Behavior in Individuals With Prader-Willi SyndromeTopiramate Effects on SIB in Prader-Willi SyndromePrader-Willi Syndrome;Self-Injurious BehaviorDrug: TopiramateEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLCompleted18 Years66 YearsBoth10N/AUnited States

先頭へ